Status:
UNKNOWN
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
This study aims to compare the pharmacokinetics and safety following administration of DWJ1568 and DWC202215 in healthy volunteers
Detailed Description
The study design is a Randomized, Open-label, Oral, Single-dose, Four-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUCt of DWJ1568 and DWC20221...
Eligibility Criteria
Inclusion
- over 19 year old
Exclusion
- Galactose intolerance
- Lapp lactase deficiency
Key Trial Info
Start Date :
November 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT06119945
Start Date
November 9 2023
End Date
December 1 2023
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H Plus YANGJI Hospital
Seoul, South Korea